H19 and Hepatic fibrosis: H19 promotes the transdifferentiation of HSCs into myofibroblasts via the TGF-β1 pathway, while the downregulation of the antifibrotic miR-148a in liver fibrosis inhibits HSCs activation by targeting ubiquitin-specific protease 4 (USP4).